Grant of Series 8 Stock Acquisition Rights to 31 Employees
First written in FY2026-H1. . Latest entry: FY2026.
18 other companies' latest entry also says "Other".
- FY2026Reduction in Series 8 stock acquisition rightsAnnual report
「Series 8 stock acquisition rights Number of stock acquisition rights: 400 [392] (Note 1) Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares: 40,000 [39,200] (Notes 1 and 3)」
Series 8 rights declined from 400 representing 40,000 common shares to 392 representing 39,200 shares at the end of the month preceding the filing date. - 2026-07-31First statedGeneral Meetings of Shareholders
「To increase the awareness of performance improvement among our directors, excluding outside directors, and employees, we request approval under Articles 236, 238 and 239 of the Companies Act to issue stock acquisition rights to our directors, excluding outside directors, and employees on particularly favorable terms, and to delegate to the Board of Directors the authority to determine the offering terms relating to the issuance based on the terms of issuance of stock acquisition rights set out below.」
As an agenda item for the 10th Annual General Meeting of Shareholders, the company has proposed approval for the issuance of stock acquisition rights to directors, excluding outside directors, and employees, capped at 400 rights representing 40,000 common shares, together with delegation to the Board of Directors of authority to determine the offering terms. Shareholder approval and issuance had not been completed as of the disclosure date. - FY2026-H1First statedAnnual report
「Resolution date 16 October 2025 Category and number of grantees (people) Company employees: 31 Number of stock acquisition rights (units)* 400 Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares: 40,000 (Note 1) Amount to be paid upon exercise (yen)* 1,411 (Note 2) Exercise period for stock acquisition rights* From 17 October 2027 to 16 October 2035」
The disclosure states that the Series 8 stock acquisition rights approved on 16 October 2025 comprised 400 rights representing 40,000 common shares and were granted to 31 employees. The exercise price was ¥1,411 and the exercise period was from 17 October 2027 to 16 October 2035, with 50% exercisable in each of 2027 and 2028.